Carisma Therapeutics (CARM) Competitors $0.40 -0.01 (-1.44%) Closing price 04:00 PM EasternExtended Trading$0.40 0.00 (-0.99%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CARM vs. EVGN, ADAP, PYRGF, VRCA, CNTB, STRO, IKNA, ANRO, CLSD, and ASRTShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Evogene (EVGN), Adaptimmune Therapeutics (ADAP), PyroGenesis Canada (PYRGF), Verrica Pharmaceuticals (VRCA), Connect Biopharma (CNTB), Sutro Biopharma (STRO), Ikena Oncology (IKNA), Alto Neuroscience (ANRO), Clearside Biomedical (CLSD), and Assertio (ASRT). Carisma Therapeutics vs. Its Competitors Evogene Adaptimmune Therapeutics PyroGenesis Canada Verrica Pharmaceuticals Connect Biopharma Sutro Biopharma Ikena Oncology Alto Neuroscience Clearside Biomedical Assertio Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment. Do analysts recommend CARM or EVGN? Carisma Therapeutics currently has a consensus price target of $1.93, suggesting a potential upside of 376.49%. Evogene has a consensus price target of $3.50, suggesting a potential upside of 180.00%. Given Carisma Therapeutics' higher probable upside, equities research analysts plainly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Evogene 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CARM or EVGN more profitable? Evogene has a net margin of -224.82% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Evogene -224.82%-102.40%-39.19% Which has better earnings and valuation, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.86-$60.48M-$1.56-0.26Evogene$8.51M0.79-$16.49M-$2.69-0.46 Does the media refer more to CARM or EVGN? In the previous week, Carisma Therapeutics and Carisma Therapeutics both had 1 articles in the media. Carisma Therapeutics' average media sentiment score of 1.89 beat Evogene's score of 0.73 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Carisma Therapeutics Very Positive Evogene Positive Which has more risk and volatility, CARM or EVGN? Carisma Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Do insiders & institutionals hold more shares of CARM or EVGN? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryCarisma Therapeutics beats Evogene on 10 of the 16 factors compared between the two stocks. Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.88M$2.44B$5.57B$9.31BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-0.269.1828.6119.73Price / Sales0.86575.37411.31174.27Price / CashN/A164.3436.0257.96Price / Book-0.604.698.235.67Net Income-$60.48M$30.99M$3.23B$257.79M7 Day Performance1.51%0.60%-0.01%0.52%1 Month Performance-5.98%7.93%5.60%8.84%1 Year Performance-68.92%-5.48%26.54%14.18% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics3.0064 of 5 stars$0.40-1.4%$1.93+376.5%-67.5%$16.88M$19.63M-0.2620Positive NewsEVGNEvogene2.506 of 5 stars$1.32-1.5%$3.50+165.2%-80.2%$7.19M$8.51M-0.49140ADAPAdaptimmune Therapeutics1.9587 of 5 stars$0.24-3.6%$1.35+460.6%-78.1%$66.26M$178.03M-0.89490PYRGFPyroGenesis Canada0.0906 of 5 stars$0.35+4.0%N/A-53.5%$66.16M$9.14M-5.9190News CoverageGap UpVRCAVerrica Pharmaceuticals4.4604 of 5 stars$0.83+17.4%$8.00+863.9%-90.5%$65.36M$7.57M-0.6940CNTBConnect Biopharma3.0875 of 5 stars$1.14-2.5%$7.00+514.0%+15.9%$64.97M$26.03M0.00110Gap UpSTROSutro Biopharma4.261 of 5 stars$0.74-2.9%$6.11+725.4%-82.2%$64.46M$62.04M-0.25240IKNAIkena Oncology2.7613 of 5 stars$1.35+1.5%$3.00+122.2%-16.5%$64.18M$9.16M-1.5770News CoverageGap UpANROAlto Neuroscience2.1394 of 5 stars$2.30-2.1%$8.50+269.6%-82.2%$63.62MN/A-0.98N/ACLSDClearside Biomedical2.0629 of 5 stars$0.82+0.3%$4.75+482.8%-33.3%$63.12M$1.66M-1.9930Positive NewsASRTAssertio1.8378 of 5 stars$0.66+0.5%$2.75+319.0%-57.1%$62.54M$124.96M-2.0520News Coverage Related Companies and Tools Related Companies Evogene Alternatives Adaptimmune Therapeutics Alternatives PyroGenesis Canada Alternatives Verrica Pharmaceuticals Alternatives Connect Biopharma Alternatives Sutro Biopharma Alternatives Ikena Oncology Alternatives Alto Neuroscience Alternatives Clearside Biomedical Alternatives Assertio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredBuffett’s Little-Known Succession PlanYou could miss out on millions buying a house - even if prices rise Joel Litman is a millionaire member of ...Altimetry | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
